Skip to main content

Table 1 Characteristics of the included studies

From: Fractional flow reserve-guided complete revascularization versus culprit-only revascularization in acute ST-segment elevation myocardial infarction and multi-vessel disease patients: a meta-analysis and systematic review

No. auther/study COR CR timing of non-IRA intervention Indication of non-IRA intervention timing of study number of centers primary endpoint secondary endpoint stent type ollow-up Treatment
1. Ghani et al. [17] 41 80 During the in-hospital phase after primary PCI or in an outpatient setting but no later than 3 weeks after STEMI FFR < 0.75 Or Diameter stenosis> 90% From June 2004 to February 2007 Single center Ejection fraction at 6 months MACE including death, non-fatal re-infarction, and additional revascularization BMS 68%
DES 20%
3 years During procedure:
glycoprotein IIb/IIIa inhibitors(45%). At discharge: not mentioned
2.DANAMI-3- PRIMULTI [19] 313 314 Two days after the initial PCI procedure and before discharge FFR ≤ 0.80 Or Diameter stenosis> 90% From March 2011 to February 2014 2 centers A composite of all-cause mortality, re-infarction, and ischemia-driven revascularization in the non-IRA Components of the primary endpoint, cardiac death, and PCI in the non-IRA BMS 1.5%
DES 94%
27 months (12–44 months) During procedure:
glycoprotein IIb/IIIa inhibitors(20%), bivalirudin(75%). At discharge:
clopidogrel 12–14%
Prasugrel 62–65%
Ticagrelor 21–23%
3.COMPAREACUTE [20] 590 590,295 During index PCI procedure (83.4%)
Delayed during index hospitalization (16.6%)
FFR ≤ 0.80 From July 2011 to October 2015 24 centers the composite of all-cause mortality, nonfatal myocardial infarction, any revascularizatio n, and cerebrovascular Components of the primary endpoints at 24,36 month s BMS 0.6% DES 98.8%
36 months During procedure:
not mentioned At discharge:
accordance with contemporary guidelines.